KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation & Amortization (CF): 2017-2024

Historic Depreciation & Amortization (CF) for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $718,000.

  • Aquestive Therapeutics' Depreciation & Amortization (CF) fell 12.58% to $139,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $565,000, marking a year-over-year decrease of 45.57%. This contributed to the annual value of $718,000 for FY2024, which is 46.62% down from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Depreciation & Amortization (CF) is $718,000, which was down 46.62% from $1.3 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Depreciation & Amortization (CF) peaked at $3.4 million during FY2020, and registered a low of $718,000 during FY2024.
  • In the last 3 years, Aquestive Therapeutics' Depreciation & Amortization (CF) had a median value of $1.3 million in 2023 and averaged $1.5 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first grew by 18.52% in 2020, then tumbled by 46.62% in 2024.
  • Aquestive Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $3.4 million in 2020, then dropped by 13.91% to $3.0 million in 2021, then decreased by 19.47% to $2.4 million in 2022, then slumped by 43.65% to $1.3 million in 2023, then plummeted by 46.62% to $718,000 in 2024.